SignaBlok presented preclinical data supporting efficacy of ligand-independent TREM-1 inhibitor in ameliorating alcoholic liver disease at the Liver Meeting 2018: American Association for the Study of Liver Diseases (AASLD)

SignaBlok presented its concept of nature-inspired rational design of macrophage-targeted imaging and drug delivery system for detection and treatment of inflammation at the 2018 World Molecular Imaging Congress

SignaBlok awarded NIGMS / NIH SBIR Phase I grant to test novel TREM-1 therapy for treatment of sepsis

SignaBlok awarded NEI / NIH SBIR Phase I grant to test new approach to prevention and treatment of neovascular retinal diseases

SignaBlok awarded NCI / NIH SBIR Phase I grant to test first-in-class TREM-1 inhibitor in combination with chemotherapy for treatment of pancreatic cancer

SignaBlok presented preclinical data on efficacy of ultra high sensitivity MRI contrast agent for diagnostic imaging of atherosclerosis in a non-rodent animal model at the 2017 World Molecular Imaging Congress

SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for retinopathy of prematurity at the 2017 ARVO Annual Meeting

SignaBlok presented preclinical data on further development of a novel ligand-independent inhibitor of TREM-1 for treatment of lung and pancreatic cancer at the 2017 AACR Annual Meeting

SignaBlok pitched on company’s magic bullet therapy for cancer, autoimmune diseases, atherosclerosis and retinopathy at the 2016 Life Sciences Summit

SignaBlok awarded NIAAA / NIH SBIR Phase I grant to test new approach to treatment of alcoholic liver disease